Venture capital financings for biopharmaceutical companies could end 2012 with a strong showing at the pace that new and early-stage firms are announcing new funding rounds, including at least three deals above $10 million kicking off the last full work week before Christmas and New Year's celebrations.
Oncology-focused Blend Therapeutics in Watertown, Massachusetts and Evanston, Illinois-based Naurex with interests in psychiatry and neurology announced Series B rounds...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

